• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

调整肿瘤学试验中的治疗转换:系统评价和报告建议。

Adjusting for Treatment Switching in Oncology Trials: A Systematic Review and Recommendations for Reporting.

机构信息

SAHMRI Women & Kids, South Australian Health & Medical Research Institute, Adelaide, Australia; School of Public Health, The University of Adelaide, Adelaide, Australia.

School of Health and Related Research, The University of Sheffield, Sheffield, England, UK.

出版信息

Value Health. 2020 Mar;23(3):388-396. doi: 10.1016/j.jval.2019.10.015. Epub 2020 Jan 23.

DOI:10.1016/j.jval.2019.10.015
PMID:32197735
Abstract

OBJECTIVES

To systematically review the quality of reporting on the application of switching adjustment approaches in published oncology trials and industry submissions to the National Institute for Health and Care Excellence Although methods such as the rank preserving structural failure time model (RPSFTM) and inverse probability of censoring weights (IPCW) have been developed to address treatment switching, the approaches are not widely accepted within health technology assessment. This limited acceptance may partly be a consequence of poor reporting on their application.

METHODS

Published trials and industry submissions were obtained from searches of PubMed and nice.org.uk, respectively. The quality of reporting in these studies was judged against a checklist of reporting recommendations, which was developed by the authors based on detailed considerations of the methods.

RESULTS

Thirteen published trials and 8 submissions to nice.org.uk satisfied inclusion criteria. The quality of reporting around the implementation of the RPSFTM and IPCW methods was generally poor. Few studies stated whether the adjustment approach was prespecified, more than a third failed to provide any justification for the chosen method, and nearly half neglected to perform sensitivity analyses. Further, it was often unclear how the RPSFTM and IPCW methods were implemented.

CONCLUSIONS

Inadequate reporting on the application of switching adjustment methods increases uncertainty around results, which may contribute to the limited acceptance of these methods by decision makers. The proposed reporting recommendations aim to support the improved interpretation of analyses undertaken to adjust for treatment switching.

摘要

目的

系统评价发表的肿瘤学试验和向英国国家卫生与保健优化研究所(National Institute for Health and Care Excellence,NICE)提交的行业报告中关于转换调整方法应用的报告质量。尽管已经开发了秩保持结构失效时间模型(rank preserving structural failure time model,RPSFTM)和逆概率 censoring 权重(inverse probability of censoring weights,IPCW)等方法来解决治疗转换问题,但这些方法在卫生技术评估中并未得到广泛接受。这种有限的接受度可能部分是由于其应用报告不佳所致。

方法

通过在 PubMed 和 nice.org.uk 上搜索,分别获得了已发表的试验和行业提交的材料。根据作者对这些方法的详细考虑,制定了一份报告建议清单,用于评估这些研究的报告质量。

结果

13 项已发表的试验和 8 项向 nice.org.uk 提交的材料符合纳入标准。RPSFTM 和 IPCW 方法实施情况的报告质量普遍较差。很少有研究表明调整方法是否是预先指定的,超过三分之一的研究没有为选择的方法提供任何理由,近一半的研究忽略了进行敏感性分析。此外,RPSFTM 和 IPCW 方法的实施方式往往不明确。

结论

对转换调整方法应用的报告不足增加了结果的不确定性,这可能是决策者对这些方法接受度有限的原因之一。所提出的报告建议旨在支持对调整治疗转换的分析进行更准确的解释。

相似文献

1
Adjusting for Treatment Switching in Oncology Trials: A Systematic Review and Recommendations for Reporting.调整肿瘤学试验中的治疗转换:系统评价和报告建议。
Value Health. 2020 Mar;23(3):388-396. doi: 10.1016/j.jval.2019.10.015. Epub 2020 Jan 23.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Adjusting survival time estimates to account for treatment switching in randomized controlled trials--an economic evaluation context: methods, limitations, and recommendations.调整生存时间估计以考虑随机对照试验中的治疗转换——经济评价背景:方法、局限性和建议。
Med Decis Making. 2014 Apr;34(3):387-402. doi: 10.1177/0272989X13520192. Epub 2014 Jan 21.
4
A cautionary tale: an evaluation of the performance of treatment switching adjustment methods in a real world case study.一个警示性的故事:在一个真实世界的案例研究中评估治疗转换调整方法的性能。
BMC Med Res Methodol. 2024 Jan 22;24(1):17. doi: 10.1186/s12874-024-02140-6.
5
Improved two-stage estimation to adjust for treatment switching in randomised trials: g-estimation to address time-dependent confounding.改进的两阶段估计法以调整随机试验中的治疗转换:用于解决时间依存性混杂的g估计法。
Stat Methods Med Res. 2020 Oct;29(10):2900-2918. doi: 10.1177/0962280220912524. Epub 2020 Mar 30.
6
Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring.两阶段估计调整随机试验中的治疗转换:一项使用逆概率加权而不是重新分类来调整的模拟研究。
BMC Med Res Methodol. 2019 Mar 29;19(1):69. doi: 10.1186/s12874-019-0709-9.
7
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
8
Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study.在复发缓解型多发性硬化症 CLARITY 试验和 CLARITY 扩展研究中,非随机脱落对治疗转换调整的影响。
Value Health. 2019 Jul;22(7):772-776. doi: 10.1016/j.jval.2018.11.015. Epub 2019 May 17.
9
Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times?在存在治疗转换的随机试验中对长期生存的因果推断:在估计反事实生存时间时是否应该重新删失?
Stat Methods Med Res. 2019 Aug;28(8):2475-2493. doi: 10.1177/0962280218780856. Epub 2018 Jun 25.
10
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.

引用本文的文献

1
Further Practical Guidance on Adjusting Time-To-Event Outcomes for Treatment Switching.关于调整治疗转换的事件发生时间结局的进一步实用指南。
Pharm Stat. 2025 Jul-Aug;24(4):e70019. doi: 10.1002/pst.70019.
2
[A comparative study of different methods for treatment switching analysis in clinical trials].[临床试验中治疗转换分析不同方法的比较研究]
Nan Fang Yi Ke Da Xue Xue Bao. 2025 May 20;45(5):1093-1102. doi: 10.12122/j.issn.1673-4254.2025.05.23.
3
Addressing treatment switching in the ALTA-1L trial with g-methods: exploring the impact of model specification.
运用g方法处理ALTA-1L试验中的治疗转换:探索模型设定的影响
BMC Med Res Methodol. 2024 Dec 20;24(1):314. doi: 10.1186/s12874-024-02437-6.
4
Exploring the characteristics, methods and reporting of systematic reviews with meta-analyses of time-to-event outcomes: a meta-epidemiological study.探索时间事件结局的系统评价与荟萃分析的特征、方法和报告:一项荟萃流行病学研究。
BMC Med Res Methodol. 2024 Nov 25;24(1):291. doi: 10.1186/s12874-024-02401-4.
5
Three new methodologies for calculating the effective sample size when performing population adjustment.三种新的方法学,用于计算执行人群调整时的有效样本量。
BMC Med Res Methodol. 2024 Nov 20;24(1):287. doi: 10.1186/s12874-024-02412-1.
6
Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate Cancer.镥-177 PSMA 与对照药物治疗转移性去势抵抗性前列腺癌及生存情况的比较
JAMA Netw Open. 2024 Sep 3;7(9):e2433863. doi: 10.1001/jamanetworkopen.2024.33863.
7
Comparative effectiveness of an individualized model of hemodialysis vs conventional hemodialysis: a study protocol for a multicenter randomized controlled trial (the TwoPlus trial).个体化血液透析模型与常规血液透析的比较效果:一项多中心随机对照试验(TwoPlus 试验)的研究方案。
Trials. 2024 Jun 28;25(1):424. doi: 10.1186/s13063-024-08281-9.
8
A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future Health Economic Models.系统评价评估复发难治性多发性骨髓瘤治疗方法的建模方法:对未来健康经济模型的关键评价和考虑。
Pharmacoeconomics. 2024 Sep;42(9):955-1002. doi: 10.1007/s40273-024-01399-3. Epub 2024 Jun 25.
9
A cautionary tale: an evaluation of the performance of treatment switching adjustment methods in a real world case study.一个警示性的故事:在一个真实世界的案例研究中评估治疗转换调整方法的性能。
BMC Med Res Methodol. 2024 Jan 22;24(1):17. doi: 10.1186/s12874-024-02140-6.
10
Comparative analysis of disease modelling for health economic evaluations of systemic therapies in advanced hepatocellular carcinoma.比较分析系统治疗晚期肝细胞癌的卫生经济评价中的疾病建模。
PLoS One. 2023 Oct 5;18(10):e0292239. doi: 10.1371/journal.pone.0292239. eCollection 2023.